MedPath

Compound Xinqi nasal spray:Research and development of an innovative traditional Chinese medicine preparation and randomized controlled single blind clinical trial

Phase 1
Not yet recruiting
Conditions
Allergic Rhinitis
Registration Number
ITMCTR2000004154
Lead Sponsor
Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

1. Patients who meet the diagnostic criteria of allergic rhinitis or have previously been diagnosed with allergic rhinitis;
2. The average total nasal symptom score (TNSS) of 1 week before treatment was more than 4;
3. No other drugs (such as intranasal glucocorticoid nasal spray, antihistamines, decongestants and anticholinergic drugs) or surgical treatment (such as endoscopic pterygoid neurectomy, endoscopic cryoablation and inferior turbinectomy) in the past 6 months;
4. Patients who are able to correctly describe their wishes, voluntarily fill in the informed consent form and agree to participate in clinical trials.

Exclusion Criteria

1. Patients with serious diseases of heart, liver, kidney and other important organs;
2. Patients complicating with other respiratory diseases, acute/chronic sinusitis and other diseases;
3. Patients with organic lesions or nasal surgery;
4. Patients known or suspected to be allergic to the drugs used in this study.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.